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ABSTRACT
Objective: The Public Committee (PC), which decides on the inclusion
and ranking of new technologies in the Israeli List of Health Services
facing a given budget, does not explicitly consider the results of eco-
nomic evaluations of the technologies discussed. The present article
includes an ex post economic examination of the PC’s 2006/2007
decisions.
Methods: The cost per quality-adjusted life-year (QALY) (CPQ) values of
the technologies approved and rejected were retrieved from national
health technologies assessments and the professional literature.
Results: CPQ values were found for 40 technologies out of the 52 that were
approved by the PC, and for 26 out of 42 randomly sampled among those
rejected. The technologies approved for inclusion produce QALYs in a
cheaper way, in general, than those rejected. A CPQ of about 50,000 new
Israeli shekels (NIS) (15,500 USDPPP [purchasing power parity adjusted
U.S. dollars]) is identiﬁed as the best discriminating value between approved
and rejected technologies. The agreement between the PC’s ranking of the
approved technologies and the ranking by CPQ is low, and the only
signiﬁcant determinant of the Committee’s ranking is the number of
patients expected to beneﬁt from the technology.
Conclusions: Although not considering CPQ data explicitly, the PC tends,
in fact, to approve technologies with relatively low CPQ. In ranking the
approved technologies, however, the PC tries to maximize the number of
persons expected to beneﬁt from the additional budget even at the expense
of possibly giving up cheaper QALYs. The size of the budget should be
determined in accordance with an Israeli value of QALY and Israeli values
of the CPQ of the technologies submitted for inclusion.
Keywords: cost per QALY, economic evaluations, Israel, national list of
health services, Public Committee.
Introduction
The Israeli National List of Health Services (INLHS), which
determines the government obligation to the population’s health
within the National Health Insurance Law, enacted in 1995, was
deﬁned at that time as the package of beneﬁts of the Clalit Health
Services, the biggest sickness fund in Israel. The cost (budget)
of the package that is allocated to the sickness funds to ﬁnance
the provision of these health services has been updated annually
with respect to input prices, demography, and new technologies.
The mean annual technological update has been less than 1%
over the last decade. The 2007 budget is about 24,000 million
new Israeli shekels (NIS) (7,400 million USDPPP [purchasing
power parity adjusted U.S. dollars]), or about 3,400 NIS (1,000
USDPPP) per capita, ﬁnancing medical care provided by the
sickness funds, including ambulatory and inpatient care. At
present, the package consists of about 2400 medicines and 1100
other technologies (there is no formal list of inpatient services).
The Israeli process of technological update consists of ﬁve
stages (for further details see [1–3]. At stage 1 (February), a call for
applications (medicines and other technologies) is issued by the
Ministry of Health (MOH), followed by the reception of these
applications (stage 2, March) and their pharmacoclinical analysis
with respect to safety, efﬁcacy, registration, acceptability, etc. by
the MOH (stage 3, April–July). In stage 4 (August–September),
the National Medical Scientiﬁc Councils and other experts are
consulted, and the MOH assigns each application a priority on a
scale of 1 to 10. The MOH’s prioritization is done by a specially
assigned team (“The New Technologies Forum”) of about 20
people representing the top management of the ministry. At that
time, the approximate update of the budget is generally known.
The considerations are mainly clinical-epidemiological (life
saving, improvement of quality of life, number of patients),
expected budget impact, co-payment by the patient and family,
acceptability, and importance to the clinical practice. The tech-
nologies included in the three top rankings (A8, A9, A10) are
submitted to the Public Committee for Updating the INLHS (PC)
for ﬁnal prioritization facing the annual budget, and the inclusion/
rejection decisions are made (stage 5, October–January). The
recommendations of the PC are generally approved by the
National Health Council and are publicly issued by the Director
General ofMOH. In recent years, the number of new technologies
submitted to MOH has been between 400 and 500 annually;
about half of themwere assigned top priority and reached the PC’s
discussions.
The 2006/2007 PC was composed of 24 people, representing
the sickness funds, MOH, the Ministry of Finance, the public,
and the Israel Medical Association. Apart from the public
representatives, other members are physicians, pharmacists, and
economists.
The preparatory work done by the MOH for the members of
PC includes the clinical-pharmacological description of the tech-
nologies and their budget impact (expected number of patients
and cost per treatment). The material available for the members
does not include, in general, economic evaluations of the pro-
posed technologies. The reason is that most of the members are
not familiar with nor do they feel comfortable with economic
evaluations as a prioritization tool. In that, the Israeli members
of the PC are not different from members of similar committees
in other countries [4,5].
In its discussions for the years 2006/2007, the PC chose 52
technologies out of 171 (speciﬁed in stage 4 of the process) to be
included in the INLHS at a total (additional) budget of 708
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million NIS (221 million USDPPP). For further details see Tamir
et al. and Shemer [6,7]. In fact, the decisions were taken in two
rounds. In the ﬁrst round (March 2006), the PC chose 34 tech-
nologies at a total budget of 474 million NIS (148 million
USDPPP), and prioritized them into 29 ranked technologies
(several technologies were ranked as a group, e.g. long-acting
insulin analogues). Public pressure led the government to supple-
ment the budget by an additional 234 million NIS (74 million
USDPPP), and in the second round (August 2006), covering the
year 2007 as well, additional 18 technologies were included, this
time without being ranked.
In light of the increasing interest in the working of national
committees setting priorities and deciding on the adoption of new
technologies, this study presents four pieces of an ex post eco-
nomic examination of the Israeli PC’s decisions in 2006: 1) the
comparison of the distribution of the cost per quality-adjusted
life-year (QALY) (CPQ) values of approved versus rejected tech-
nologies. Even if not explicitly considered, CPQ values might be
correlated with other characteristics that are considered by the
members of the PC (e.g., number of patients, budget impact,
clinical efﬁcacy and usefulness, etc.), and the question is whether,
ex post, the PC adopts technologies that produce QALYs more
cheaply, 2) the identiﬁcation of a “CPQ threshold” that best
discriminates between technologies approved and rejected. A
threshold below which technologies are approved, and above
which they are rejected, does not exist anywhere [8–10]. These
reviews suggest, however, “informal thresholds,” such as the value
of £30,000 GBP in the United Kingdom. Although the Israeli
procedure is based on a ﬁxed budget rather than a ﬁxed threshold,
the second piece of analysis tries to identify such a threshold, using
the CPQs of the technologies approved and rejected by the Israeli
PC. Doing so, we add to several similar earlier examinations in
other systems (e.g., Devlin and Parkin [11] in the United
Kingdom); 3) the agreement between the PC’s ranking of the
technologies approved in the ﬁrst round and the ranking of the
same technologies by their CPQ values; and 4) the estimated
importance of the CPQ ranking, number of patients, cost per
patient, and budget impact in the PC’s ranking of the technologies
approved in the ﬁrst round.
Methods
Retrieving CPQ Data
CPQ data for all 52 technologies approved for inclusion and for a
random sample of 42 out of 116 that were rejected were searched
over the Internet, including several electronic databases. First
priority was given to national technology assessments prepared in
England, Canada, Australia, Scotland, and others. Second priority
was given to reviews of technologies assessments, and third, to a
single published article assessing the technology. In cases where
more than one value was retrieved in a given priority level or a
range of values was given, a geometric mean, which handles
extreme values better than the arithmetic mean, was taken. In
some cases, when the results applied to speciﬁc patients groups
(e.g., men and women, or different comparators), further careful
judgment was exercised in order to derive a single value. All CPQ
values were inﬂated to the year 2007 in their own currencies, and
then converted into NIS using the 2007 purchasing power parity
(PPP) exchange rates.
Comparing the Distribution of the CPQ Values of
Approved versus Rejected Technologies
T-test and the Mann-Whitney-Wilcoxon test were used to test the
similarity of the distributions.
An Identiﬁcation of a “CPQ Threshold”
As we look for a threshold with one variable only (CPQ), the
receiver operating characteristics (ROC) curve tool is useful. The
“revealed CPQ threshold,” namely, the PC’s willingness to pay
for a QALY, was identiﬁed using ROC Curve [12]. The ROC
Curve calculations indicate the CPQ (the “test” variable) value
that best discriminate the technologies approved from those
rejected (the “truth standard”). The best discrimination is
achieved when the expected utility of the partition is maximized,
where expected utility is the weighted sum of sensitivity and
speciﬁcity, the weights being the prior probabilities of approval
and rejection, respectively.
The Agreement between the PC’s Ranking and the
Ranking of the Same Technologies by Their CPQ Values
This analysis focuses on the technologies approved in the ﬁrst
round of discussion, in which the technologies approved were
also ranked according to the PC’s priorities. The question exam-
ined is to what degree the PC’s ranking agrees with the ranking
of the same technologies by their CPQ values. Agreement
between rankings was tested using the Intraclass Correlation
Coefﬁcient (ICC) [13], with one-way and two-way methods.The
range of the ICC may be between 0.0 and 1.0. The ICC will be
high when there is little variation between the ranks given to each
technology by the two rankings. The ICC is an improvement over
Pearson’s r and Spearman’s r, as it takes into account the differ-
ences in ratings for individual technologies, along with the cor-
relation between rankings.
The Determinants of the PC’s Ranking
The importance of several characteristics of the technologies
approved in the ﬁrst round of discussion in their ranking by the
PC was estimated using linear regression in four steps. In the ﬁrst
speciﬁcation, only the ranking by CPQ was included. In the
second speciﬁcation, the number of patients expected to beneﬁt
from the technology was added. In the third and fourth speciﬁ-
cations, the cost per patient and the budget impact were added
respectively.
Results
Similarly to the experience of Devlin and Parkin [10], we also
found the collection of the CPQ data very difﬁcult. The main
difﬁculty was the need to verify that the technologies were indeed
evaluated for the use speciﬁed by the application to the PC and
that the comparator was indeed the actual practice being chal-
lenged. The search results showed that out of the 34 technologies
that were approved for inclusion in the ﬁrst round, valid and
reliable CPQ data were found for 25 (74%). Out of the 18
approved technologies in the second round, the CPQ for 15 was
identiﬁed (83%). A total of 40 CPQ values were found for the 52
technologies approved (77%). For 26 out of 42 technologies not
approved (62%), valid and reliable CPQ data were found. An
Appendix available upon request provides details on the search
results and sources.
The Distribution of the Cost Per QALY Values of the
Technologies Approved and Rejected
Figure 1 portrays the distribution of the CPQ of the 40 technolo-
gies approved and of the 26 technologies rejected by the PC in
2006/2007. Clearly, a larger mass of the distribution in the
technologies approved is found in lower CPQ. Although 50% of
Evaluation of the 2006/2007 Decisions on the INLHS 203
the technologies approved have CPQ lower than 50,000 NIS
(15,600 USDPPP), only 15% of the technologies rejected do so.
The mean CPQ among the technologies approved is 117,295 NIS
(36,650 USDPPP) with a standard deviation of 211,699 NIS
(66,150 USDPPP), and among the technologies rejected; the
numbers are 171,820 (53,700USDPPP) and 212,385NIS (66,400
USDPPP), respectively. The t-statistic is 0.84, which indicates no
difference between the means. Nevertheless, a more suitable test
for the equality of the entire distribution is the nonparametric
Mann-Whitney-Wilxocon test. This test results in u = 350 and its
standardized normal approximation z = -2.2, which indicates
that the distribution of CPQ of the technologies included is
signiﬁcantly (P = 0.013) “smaller” than (placed to the left of) that
of the technologies rejected.
Among the technologies approved for inclusion, 10 technolo-
gies have CPQ below 30,000 NIS (9,400 USDPPP), including 4
which were found to be cost-saving (for which no extra budget
should have been assigned). On the other end, three technologies
have CPQ above 250,000 NIS (78,100 USDPPP). They include
Zomera (Novartis, Basel, Switzerland), Avastin (Genentech/
Roche, San Francisco, CA), and Myozyme (Genzyme, Cam-
bridge, MA), with a CPQ of 1,287,500 NIS (402,000 USDPPP).
Among the technologies rejected, one (Lustral; Pﬁzer- New
York, NY) was found dominated by current practice and was
excluded from the analysis (leading to an underestimate of the
CPQ of the technologies rejected). Zyban (GlaxoSmithKline,
London, UK), a smoking-cessation aid, has the lowest
CPQ—6,500 NIS (2,000 USDPPP). Six technologies have CPQ
higher than 250,000 NIS (78,100 USDPPP), with the highest
CPQs belonging to Forteo (Eli Lilly, Indianapolis, IN) and Gliadel
(MGI Pharma, Minneapolis, MN).
Can a CPQ Threshold Be Inferred from the
PC’s Decisions?
The area under the ROC curve, which measures the probability
that randomly selected instances of approval and rejection would
be ranked correctly by CPQ, is 0.666 (95% conﬁdence interval
[CI] is 0.535, 0.797], which is considered a fair accuracy by the
usual standards (0.5 signiﬁes meaningless relation, 1 represent a
perfect test). The CPQ value with the highest accuracy is 50,750
NIS (15,900 USDPPP) (corresponding to true positive rate of
0.5 and false positive rate of 0.154). This threshold is better,
however, in identifying technologies that are likely to be
approved (CPQ < 50,750) rather than predicting rejection.
The Degree of Agreement between the PC’s Ranking of
the 25 Technologies Approved in the First Round and
the Ranking by CPQ
As was mentioned earlier, in the ﬁrst round of its discussions,
the PC ranked the technologies recommended for inclusion by
their importance. For 25 technologies, CPQ values were found.
Figure 2 shows the association between the ranking of the PC
and their CPQ. A linear relationship was found superior to
other speciﬁcations and is shown in the ﬁgure. A positive associa-
tion is indicated, but the rank correlation is 0.353, which is not
signiﬁcantly different than zero (P = 0.124). Several “outliers”
stand out; for example, Ezetrol (MSD, Whitehouse Station, NJ),
Zomera, and Keppra (UCB, Brussels, Belgium) have CPQ much
too high—and Xeloda (Roche, Basel, Switzerland), Plavix (BMS-
Sanoﬁ-Aventis, New York, NY), and Zyprexa—too low—for
their rankings by the Committee.
The question is, however, not of correlation but of agreement
between the rankings. The degree of agreement was assessed by
use of the ICC in two models. In a one-way random effect model
where the technologies effects are random, ICC = 0.367 and the
hypothesis of no agreement is rejected (P = 0.043). In a two-way
effects model (both random and mixed), ICC = 0.357, and the no
agreement hypothesis cannot be rejected (P = 0.057). We con-
clude that the degree of agreement between the PC ranking and
ranking by CPQ is low, and only marginally signiﬁcant.
The Importance of the CPQ, Number of Patients, Cost
Per Patient, and Budget Impact in the Public
Committee’s Ranking
Table 1 presents four speciﬁcations (denoted by I–IV) of the
equation describing the determinants of the PC’s ranking of the
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Figure 1 The distribution of CPQ of technologies approved and rejected (%).
CPQ, cost per quality-adjusted life-year.
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Figure 2 CPQ of the technologies approved
in the ﬁrst round ordered by the PC’s ranking (NIS,
1 USDPPP = 3.2 NIS). CPQ, cost per quality-
adjusted life-year; NIS, new Israeli shekels; PC,
Public Committee; USDPPP, purchasing power
parity adjusted U.S. dollars.
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25 technologies of the ﬁrst round. The potential determinants are
CPQ ranking, number of patients, cost per patient, and budget
impact (which is the product of the latter two). From speciﬁca-
tions I (rank CPQ only), II (rank CPQ and the number of patients
expected to beneﬁt from the technology), and III (rank CPQ and
the number of patients expected to beneﬁt from the technology
and the cost per patient), the clear conclusion is that the only
factor that signiﬁcantly affects the ranking is the number of
patients expected to enjoy the technology. The higher the number
of patients, the higher the ranking (namely, lower ordering
number) of that technology. It should be pointed out that this
relationship is largely affected by the large number of persons
expected to beneﬁt from the ﬁrst three technologies. In the ﬁrst
priority are two antihypercholesterolemia drugs from which
28,000 persons are expected to beneﬁt. The second place
includes antihypertension and angiotensin II receptor antagonists
with an estimated number of users of 24,175 persons. Long-
acting insulin analogues occupy the third place, with expected
number of patients of 7,000 (the overall average number of
patients expected to beneﬁt from the technologies approved in
the ﬁrst round is 4,000).
Neither the ranking by CPQ (nor the CPQs themselves) nor
the cost of the treatment and the budget impact have any effect
on the committee ranking. The fourth speciﬁcation (IV), which
adds the budget impact as an explanatory variable, might suffer
from multicollinearity among the number of patients, cost per
patient, and budget impact, which rendered the number of
patients to have an insigniﬁcant effect.
Discussion
Like several PCs in other health systems, the Israeli Committee for
Updating the INLHS does not consider explicitly the economic
evaluations of the technologies discussed. In general, economic
evaluations are used to support decisions on public ﬁnance of
technologies in twoways. First, by including the technologies with
the lowest cost per QALY until the predetermined budget is
exhausted, the number of QALYs gained for the given budget is
maximized. Alternatively, if a predetermined social willingness to
pay for a QALY is used, technologies will be included as long as
they “produce” QALYs at a cost lower than this value, regardless
of their budget impact.
We examined the PC’s decisions during the 2006/2007 discus-
sions from both perspectives. The ﬁndings indicate that, indeed,
the ranking of the technologies by the committee does not corre-
spond to the ranking by CPQ. In fact, the committee’s ranking is
observationally inﬂuenced mainly by the number of persons
expected to beneﬁt from the inclusion of the technology in the list
ﬁnanced by public monies. Neither the cost per person nor the
budget impact affects the committee’s ranking. The committee’s
revealed preference is, consequently, for maximizing the number
of persons expected to beneﬁt from the additional budget at the
likely expense of giving up cheaper QALYs. Nevertheless, this
consideration does not apply explicitly to the approval/rejection
decision, as is indicated by the general lack of data on the number
of persons expected to beneﬁt from the technologies that were
rejected.
The CPQ values of the technologies approved are generally
lower than the values of those rejected, implying that the factors
considered by the members of the PC in their decisions (e.g.,
number of patients, budget impact, clinical efﬁcacy and useful-
ness, etc.) are correlated with CPQ data. On the margin,
although discriminating between the technologies approved and
rejected by CPQ results only in a fair accuracy, a CPQ lower than
50,000 NIS (15,500 USDPPP) might be a good predictor of
approval. This is a relatively low threshold in international
comparisons.
Elsewhere (Shmueli A, Nissan-Engelcin E. A preliminary esti-
mate of the Israeli VOSL and its implications for the update
of the national list of health services, Unpublished 2007 [in
Hebrew]), it is argued, based on a thorough review of recent
Israeli and international estimates of the value of statistical life,
that a reasonable value of QALY (the Israeli willingness
to pay for a QALY) might be 250,000 NIS (78,000 USDPPP).
Three technologies were approved but are beyond that threshold.
Each one, however, has its own “particular social justiﬁcation”
for inclusion: Zomera is a treatment for men with bone
metastases from prostate cancer. One of the arguments for its
inclusion was a gender fairness argument with respect to the
inclusion of several treatments for breast cancer for women.
Avastin for colorectal cancer attracted public concern following a
hunger strike of cancer patients in summer 2006. Finally,
Myozyme is a treatment for 11 people with the orphan disease
Pompe. We note, however, that 77% of the technologies rejected
have CPQ lower than 250,000 NIS as well. Probably tech-
nologies with CPQ higher than 250,000 NIS are screened out,
indirectly as well, by MOH in stage 4, as described earlier.
Two broad policy conclusions emerge. First, although the
updating process is well structured and staged, much more atten-
tion (although naturally not the ﬁnal word) should be given to
economic evaluations data in the PC’s decision-making process.
The practical derivative is that effort should be invested in creating
an Israeli organization that will create guidelines for the prepara-
tion of economic evaluations by the manufacturers, will evaluate
the material submitted, and will create a national databank on the
cost ofmedical services and technologies, as well as on health state
utilities. “Importing” CPQ values from other countries, as was
done in this article, although being the only way to evaluate the
PC’s decisions at present, is clearly inadequate, as both costs of
medical care and utilities of health states differ among societies.
Furthermore, the ﬁnding that for more than a quarter of the
technologies, a CPQ value could not be found, might indicate that
in Israel, technologies are discussed earlier than in other health
systems. The CPQ information should be available to the
Table 1 The determinants of the Public Committee’s ranking
Coefﬁcients Standard error t-value
I
Intercept 7.186 2.702 2.659*
Rank CPQ 0.347 0.215 1.611
R2 0.120
II
Intercept 9.572 2.503 3.824*
Rank CPQ 0.278 0.188 1.476
N of patients -4.129E-04 1.529E-04 -2.701*
R2 0.374
III
Intercept 9.318 2.667 3.494*
Rank CPQ 0.264 0.197 1.343
N of patients -3.938E-04 1.658E-04 -2.375*
Cost per patient 7.976E-06 2.270E-05 0.351
R2 0.378
IV
Intercept 9.320 2.745 3.396*
Rank CPQ 0.269 0.204 1.320
N of patients -3.565E-04 2.413E-04 -1.477
Cost per patient 1.414E-05 3.660E-05 0.386
Budget impact -0.023 0.104 -0.219
R2 0.380
*Signiﬁcant at 0.05.
CPQ, cost per quality-adjusted life-year.
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members of the PC and will support their decisions on the
inclusion of technologies within the given budget.
Second, a more serious and comprehensive public discussion
should lead the determination of the budget for new technolo-
gies. At present, the public discussion is between those in favor of
an assured predetermined yearly update (e.g., 2–3%) and those
who want to maintain the present scheme, namely, a yearly
decision determined within governmental priorities. This discus-
sion should review all public monies allocated to raise the safety
of the public—in workplaces, on the roads, food regulation, in
the Israeli Defense Forces, health care, etc.—in light of an Israeli
value of life. Recently, for example, the Ministries of Transport
and Finance issued guidelines for the evaluation of transporta-
tion projects [14]. These guidelines specify that the value of life
should be taken as 5 million NIS (1.6 million USDPPP), which,
under regular assumptions, translates into a value of QALY of
about 125,000 NIS (39,000 USDPPP). If this value reﬂects the
Israeli willingness to pay for a QALY, the budget for the inclusion
of new technologies in any year should be determined so that the
CPQ of the least favorable technology included be that value.
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Supporting information for this article can be found at: http://
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